AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering toRead More
Partnering to unlock the true potential of cannabis in medical care
Innoplexus supports the European Summer School in Logic, Language and Information
In late 90s, internet solved the problem of data access. Then came the explosion of data with the web search and social media. Necessity to find relevant data & analyse it in specific context gave birth to the new field of science, the data sciences. The inter-disciplinary fields spans software development, data persistence & warehousing, advanced mathematics & statistics and artificial intelligence, making it difficult to learn for not only beginners but also people with years of experience.
Innoplexus develops cutting-edge technology products and solutions based on Information Retrieval, Network Analysis, Computer Vision and Ontologies. The interface between linguistics, logic and computation, with special emphasis on human linguistic and cognitive ability is their core business just as the focus of study of the European Summer School in Logic, Language and Information (ESSLLI).
To that end, Innoplexus whole-hearily supports the initiative of ESSLLI organized by the Association for Logic, Language and Information (FoLLI). The conference is held over two weeks of the European Summer and offers about 50 courses at introductory and advanced levels. It attracts around 500 participants from all over the world.
The European Summer School in Logic, Language and Information is an event organized every year in a different European country. This year the program is being hosted in Bulgaria from 6-17 August 2018 by Sofia University and the Institute of Information and Communication Technologies, Bulgarian Academy of Sciences (IICT-BAS), supported by the Association for Computational Linguistics.
Innoplexus is proud to be a Gold sponsor of ESSLLI 2018, together with the other sponsors including CLARIN, Association for Symbolic Logic, Ontotext, Springer, Lenovo, European Mathematical Society, Facebook AI research, etc.
Featured News
Partex and Singapore’s Experimental Drug Development Centre collaborate to bring
Frankfurt, Germany, 3rd June 2024, 9am CET Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to…
Partex Partners with Lupin to Revolutionize Drug Discovery through AI-Driven
Frankfurt, Germany, 23 April 2024 – Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to…
Partex NV announces collaboration with Althea DRF Lifesciences to provide
Frankfurt, Germany; 28 March 2024 – Partex Group, a pioneer in AI-driven drug discovery, announces a collaboration with Althea DRF…
Innovative AI technology in oncology: Partex Group presents results from
During the German Cancer Congress 2024 in Berlin, the companies Innoplexus AG /Amrit AG, companies of Partex N.V., presented the…
Partex NV Forges Collaboration with Sanofi in AI-Based Dossier Enrichment
Frankfurt, Germany; 14 March 2024 Partex Group, a pioneer in AI-driven drug discovery, today announces a collaboration with global pharmaceutical…
Innoplexus and AIO Studien gGmbH are jointly announcing the start
January 02, 2024 – Innoplexus and Amrit AG, members of the Partex NV Group, providers of innovative technology for health…
Strategic partnership announcement: Innoplexus holding company Partex NV is pleased
Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience. Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to announce…
AI supports targeted therapy recommendations fortumor diseases – BMBF funds
The treatment and support of patients with advanced tumor diseases is a complex task involving numerous disciplines. For the interdisciplinary…
Innoplexus and Innovatrix capital partner to bring about new risk-transfer
Artificial Intelligence (AI) pioneer Innoplexus and London based Parametric Insurance start-up, Innovatrix Capital, collaborating upon using AI & Machine Learning…
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence to expedite PIM kinase inhibitor development ESCHBORN, Germany, May 30,…
